| Catalytic in vivo protein knockdown by small-molecule PROTACs DP Bondeson, A Mares, IED Smith, E Ko, S Campos, AH Miah, ... Nature chemical biology 11 (8), 611-617, 2015 | 1174 | 2015 |
| The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines ER Benjamin, JJ Flanagan, A Schilling, HH Chang, L Agarwal, E Katz, ... Journal of Inherited Metabolic Disease: Official Journal of the Society for …, 2009 | 213 | 2009 |
| Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders KJ Valenzano, R Khanna, AC Powe Jr, R Boyd, G Lee, JJ Flanagan, ... Assay and drug development technologies 9 (3), 213-235, 2011 | 200 | 2011 |
| The yeast orthologue of GRASP65 forms a complex with a coiled-coil protein that contributes to ER to Golgi traffic R Behnia, FA Barr, JJ Flanagan, C Barlowe, S Munro The Journal of cell biology 176 (3), 255-261, 2007 | 181 | 2007 |
| Signal recognition particle binds to ribosome-bound signal sequences with fluorescence-detected subnanomolar affinity that does not diminish as the nascent chain lengthens JJ Flanagan, JC Chen, Y Miao, Y Shao, J Lin, PE Bock, AE Johnson Journal of biological chemistry 278 (20), 18628-18637, 2003 | 159 | 2003 |
| Cholesterol exposure at the membrane surface is necessary and sufficient to trigger perfringolysin O binding JJ Flanagan, RK Tweten, AE Johnson, AP Heuck Biochemistry 48 (18), 3977-3987, 2009 | 151 | 2009 |
| The pharmacological chaperone 1‐deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha‐glucosidase JJ Flanagan, B Rossi, K Tang, X Wu, K Mascioli, F Donaudy, MR Tuzzi, ... Human mutation 30 (12), 1683-1692, 2009 | 128 | 2009 |
| Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer JJ Flanagan, Y Qian, SM Gough, M Andreoli, M Bookbinder, G Cadelina, ... Cancer research 79 (4_Supplement), P5-04-18-P5-04-18, 2019 | 127 | 2019 |
| A GCase chaperone improves motor function in a mouse model of synucleinopathy F Richter, SM Fleming, M Watson, V Lemesre, L Pellegrino, B Ranes, ... Neurotherapeutics 11 (4), 840-856, 2014 | 110 | 2014 |
| Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice ER Benjamin, R Khanna, A Schilling, JJ Flanagan, LJ Pellegrino, ... Molecular Therapy 20 (4), 717-726, 2012 | 110 | 2012 |
| Methods of in situ detection of nucleic acids Y Luo, HY Wang, JJ Flanagan, S Chen US Patent App. 13/575,936, 2013 | 98 | 2013 |
| A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry disease X Wu, E Katz, MCD Valle, K Mascioli, JJ Flanagan, JP Castelli, ... Human mutation 32 (8), 965-977, 2011 | 98 | 2011 |
| The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease R Khanna, JJ Flanagan, J Feng, R Soska, M Frascella, LJ Pellegrino, ... PloS one 7 (7), e40776, 2012 | 96 | 2012 |
| The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer LB Snyder, JJ Flanagan, Y Qian, SM Gough, M Andreoli, M Bookbinder, ... Cancer Res 81 (13), 44, 2021 | 89 | 2021 |
| Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase A in Fabry patients when co-administered with infused agalsidase DG Warnock, DG Bichet, M Holida, O Goker-Alpan, K Nicholls, M Thomas, ... PLoS One 10 (8), e0134341, 2015 | 80 | 2015 |
| Targeting nuclear receptors with PROTAC degraders JJ Flanagan, TK Neklesa Molecular and cellular endocrinology 493, 110452, 2019 | 67 | 2019 |
| Method to predict response to pharmacological chaperone treatment of diseases E Benjamin, HV Do, X Wu, J Flanagan, B Wustman US Patent 8,592,362, 2013 | 58 | 2013 |
| Duvoglustat HCl increases systemic and tissue exposure of active acid α-glucosidase in Pompe patients co-administered with alglucosidase α P Kishnani, M Tarnopolsky, M Roberts, K Sivakumar, M Dasouki, ... Molecular Therapy 25 (5), 1199-1208, 2017 | 54 | 2017 |
| Development of a multiantigen panel for improved detection of Borrelia burgdorferi infection in early Lyme disease LJ Lahey, MW Panas, R Mao, M Delanoy, JJ Flanagan, SR Binder, ... Journal of clinical microbiology 53 (12), 3834-3841, 2015 | 53 | 2015 |
| Sec22p export from the endoplasmic reticulum is independent of SNARE pairing Y Liu, JJ Flanagan, C Barlowe Journal of Biological Chemistry 279 (26), 27225-27232, 2004 | 53 | 2004 |
